Business Description
Ipca Laboratories Ltd
ISIN : INE571A01038
Compare
Compare
Traded in other countries / regions
IPCALAB.India IPO Date
1994-05-06Description
Ipca Laboratories Ltd is a specialty and generic drug manufacturing company. The company's principal activity is Development, Manufacturing and Marketing of Pharmaceuticals Products. The company operates multiple subsidiaries with revenue generation split roughly between India and the rest of the world. Ipca's products are exported to more than 100 countries across the globe. Ipca has only one reportable primary business segment, pharmaceuticals.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.52 | |||||
| Equity-to-Asset | 0.54 | |||||
| Debt-to-Equity | 0.32 | |||||
| Debt-to-EBITDA | 1.47 | |||||
| Interest Coverage | 6.72 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 6.54 | |||||
| Beneish M-Score | -2.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.7 | |||||
| 3-Year EBITDA Growth Rate | 2.8 | |||||
| 3-Year EPS without NRI Growth Rate | -9.9 | |||||
| 3-Year FCF Growth Rate | 5.5 | |||||
| 3-Year Book Growth Rate | 17.1 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.09 | |||||
| 9-Day RSI | 63.8 | |||||
| 14-Day RSI | 64.23 | |||||
| 6-1 Month Momentum % | 27.89 | |||||
| 12-1 Month Momentum % | 42.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.13 | |||||
| Quick Ratio | 1.22 | |||||
| Cash Ratio | 0.39 | |||||
| Days Inventory | 283.52 | |||||
| Days Sales Outstanding | 65.56 | |||||
| Days Payable | 89.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.15 | |||||
| Dividend Payout Ratio | 0.1 | |||||
| Forward Dividend Yield % | 0.15 | |||||
| 5-Year Yield-on-Cost % | 1.62 | |||||
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | -2.71 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 63.88 | |||||
| Operating Margin % | 11.92 | |||||
| Net Margin % | 7.89 | |||||
| FCF Margin % | 4.36 | |||||
| ROE % | 9.53 | |||||
| ROA % | 6.07 | |||||
| ROIC % | 8.22 | |||||
| ROC (Joel Greenblatt) % | 18.03 | |||||
| ROCE % | 13.92 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 59.73 | |||||
| PE Ratio without NRI | 67.97 | |||||
| Shiller PE Ratio | 57.74 | |||||
| Price-to-Owner-Earnings | 60.74 | |||||
| PEG Ratio | 3.56 | |||||
| PS Ratio | 4.72 | |||||
| PB Ratio | 5.48 | |||||
| Price-to-Tangible-Book | 5.71 | |||||
| Price-to-Free-Cash-Flow | 108.29 | |||||
| Price-to-Operating-Cash-Flow | 41.84 | |||||
| EV-to-EBIT | 33.91 | |||||
| EV-to-EBITDA | 25.66 | |||||
| EV-to-Revenue | 4.85 | |||||
| EV-to-FCF | 111.35 | |||||
| Price-to-Projected-FCF | 3.49 | |||||
| Price-to-Peter-Lynch-Fair-Value | 7.62 | |||||
| Price-to-Graham-Number | 4.24 | |||||
| Price-to-Net-Current-Asset-Value | 69.58 | |||||
| Earnings Yield (Greenblatt) % | 2.95 | |||||
| FCF Yield % | 0.92 | |||||
| Forward Rate of Return (Yacktman) % | 20.14 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ipca Laboratories Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 71,485.6 | ||
| EPS (TTM) (₹) | 22.25 | ||
| Beta | 0.8 | ||
| Volatility % | 27.55 | ||
| 14-Day RSI | 64.23 | ||
| 14-Day ATR (₹) | 42.884208 | ||
| 20-Day SMA (₹) | 1271.4475 | ||
| 12-1 Month Momentum % | 42.32 | ||
| 52-Week Range (₹) | 670 - 1373.95 | ||
| Shares Outstanding (Mil) | 253.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ipca Laboratories Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ipca Laboratories Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ipca Laboratories Ltd Frequently Asked Questions
What is Ipca Laboratories Ltd(BOM:524494)'s stock price today?
The current price of BOM:524494 is ₹1328.95. The 52 week high of BOM:524494 is ₹1373.95 and 52 week low is ₹670.00.
When is next earnings date of Ipca Laboratories Ltd(BOM:524494)?
The next earnings date of Ipca Laboratories Ltd(BOM:524494) is 2024-05-29 Est..
Does Ipca Laboratories Ltd(BOM:524494) pay dividends? If so, how much?
The Dividend Yield %  of Ipca Laboratories Ltd(BOM:524494) is 0.15% (As of Today), Highest Dividend Payout Ratio of Ipca Laboratories Ltd(BOM:524494) was 0.22. The lowest was 0.03. And the median was 0.12. The  Forward Dividend Yield % of Ipca Laboratories Ltd(BOM:524494) is 0.15%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers